{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:31:30Z","timestamp":1793658690912,"version":"4.5.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"publisher","award":["SML20150301"],"award-info":[{"award-number":["SML20150301"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["Z171100001117015"],"award-info":[{"award-number":["Z171100001117015"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012491","name":"Beijing Municipal Excellent Talents Foundation","doi-asserted-by":"publisher","award":["2017000021223ZK38"],"award-info":[{"award-number":["2017000021223ZK38"]}],"id":[{"id":"10.13039\/100012491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pleural effusion is a common clinical problem in patients with cancer. We aimed to summarize all the known prognostic indicators of malignant pleural effusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We did a systematic review and meta-analysis with a systematic literature search. All prospective or retrospective cohort studies that estimated the prognostic factors of malignant pleural effusion were enrolled. Mantel\u2013Haenszel method was used to calculate the pooled hazard ratio (HR) and 95% confidence interval (CI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eventually, we identified 82 studies with a total of 10,748 patients that met our inclusion criteria. The LENT score showed a good prognostic value (HR 1.97, 95% CI 1.67\u20132.31) so did the LENT score item. In addition, clinical parameters like stage (HR 1.68, 95% CI 1.25\u20132.25), distant metastasis (HR 1.62, 95% CI 1.38\u20131.89), EGFR mutation (HR 0.65, 95% CI 0.56\u20130.74), serum biological parameters like hemoglobin (HR 1.56, 95% CI 1.17\u20132.06), albumin (HR 1.71, 95% CI 1.25\u20132.34), C-reaction protein (HR 1.84, 95% CI 1.49\u20132.29), VEGF (HR 1.70, 95% CI 1.18\u20132.43) and pleural effusion biological parameters like PH (HR 1.95, 95% CI 1.46\u20132.60), glucose (HR 1.75, 95% CI 1.18\u20132.61), VEGF (HR 1.99, 95% CI 1.67\u20132.37), and survivin (HR 2.90, 95% CI 1.17\u20137.20) are also prognostic factors for malignant pleural effusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For malignant pleural effusion, LENT score and its items are valuable prognostic biomarkers, so do the clinical parameters like stage, distant metastasis, EGFR mutation, the serum biological parameters like hemoglobin, albumin, C-reaction protein, VEGF and the pleural effusion biological parameters like PH, glucose, VEGF and survivin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12935-022-02518-w","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T08:02:31Z","timestamp":1645689751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Prognostic biomarkers of malignant patients with pleural effusion: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Peng","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1154-7920","authenticated-orcid":false,"given":"Huan-Zhong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"issue":"8","key":"2518_CR1","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMra1403503","volume":"378","author":"D Feller-Kopman","year":"2018","unstructured":"Feller-Kopman D, Light R. Pleural disease. N Engl J Med. 2018;378(8):740\u201351.","journal-title":"N Engl J Med"},{"issue":"4","key":"2518_CR2","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.chest.2016.11.010","volume":"151","author":"N Taghizadeh","year":"2017","unstructured":"Taghizadeh N, Fortin M, Tremblay A. US hospitalizations for malignant pleural effusions: data from the 2012 national inpatient sample. Chest. 2017;151(4):845\u201354.","journal-title":"Chest."},{"issue":"1","key":"2518_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccm.2017.11.004","volume":"39","author":"R Asciak","year":"2018","unstructured":"Asciak R, Rahman NM. Malignant pleural effusion: from diagnostics to therapeutics. Clin Chest Med. 2018;39(1):181\u201393.","journal-title":"Clin Chest Med"},{"issue":"1","key":"2518_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39\u201351.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2518_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/1749-8090-7-121","volume":"7","author":"J Han","year":"2012","unstructured":"Han J, Cao S, Zhang K, et al. Fluorescence in situ hybridization as adjunct to cytology improves the diagnosis and directs estimation of prognosis of malignant pleural effusions. J Cardiothorac Surg. 2012;7(1):121.","journal-title":"J Cardiothorac Surg"},{"issue":"4","key":"2518_CR6","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/resp.12496","volume":"20","author":"JM Porcel","year":"2015","unstructured":"Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions. Respirology (Carlton, Vic). 2015;20(4):654\u20139.","journal-title":"Respirology (Carlton, Vic.)"},{"issue":"12","key":"2518_CR7","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/thoraxjnl-2014-205285","volume":"69","author":"AO Clive","year":"2014","unstructured":"Clive AO, Kahan BC, Hooper CE, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69(12):1098\u2013104.","journal-title":"Thorax"},{"issue":"7","key":"2518_CR8","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S1470-2045(18)30294-8","volume":"19","author":"I Psallidas","year":"2018","unstructured":"Psallidas I, Kanellakis NI, Gerry S, et al. Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis. Lancet Oncol. 2018;19(7):930\u20139.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2518_CR9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1159\/000489315","volume":"96","author":"J Abisheganaden","year":"2018","unstructured":"Abisheganaden J, Verma A, Dagaonkar RS, Light RW. An observational study evaluating the performance of LENT score in the selected population of malignant pleural effusion from lung adenocarcinoma in Singapore. Respiration. 2018;96(4):308\u201313.","journal-title":"Respiration"},{"issue":"12","key":"2518_CR10","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1111\/resp.13837","volume":"25","author":"JC Quek","year":"2020","unstructured":"Quek JC, Tan QL, Allen JC, Anantham D. Malignant pleural effusion survival prognostication in an Asian population. Respirology. 2020;25(12):1283\u201391.","journal-title":"Respirology"},{"issue":"9","key":"2518_CR11","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1200\/JCO.2013.50.5453","volume":"32","author":"JS Ryu","year":"2014","unstructured":"Ryu JS, Ryu HJ, Lee SN, et al. Prognostic impact of minimal pleural effusion in non-small-cell lung cancer. J Clin Oncol. 2014;32(9):960\u20137.","journal-title":"J Clin Oncol"},{"key":"2518_CR12","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical research ed). 2009;339:b2535.","journal-title":"BMJ (Clinical research ed.)."},{"issue":"24","key":"2518_CR13","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","volume":"17","author":"MKB Parmar","year":"1998","unstructured":"Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815\u201334.","journal-title":"Stat Med"},{"issue":"9","key":"2518_CR14","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jclinepi.2013.03.003","volume":"66","author":"L Hartling","year":"2013","unstructured":"Hartling L, Milne A, Hamm MP, et al. Testing the Newcastle Ottawa Scale showed low reliability between individual reviewers. J Clin Epidemiol. 2013;66(9):982\u201393.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2518_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1378\/chest.117.1.73","volume":"117","author":"CM Burrows","year":"2000","unstructured":"Burrows CM, Mathews C, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions\u2014an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest. 2000;117(1):73\u20138.","journal-title":"Chest"},{"issue":"1","key":"2518_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejim.2009.09.012","volume":"21","author":"MO Ozyurtkan","year":"2010","unstructured":"Ozyurtkan MO, Balci AE, Cakmak M. Predictors of mortality within three months in the patients with malignant pleural effusion. Eur J Intern Med. 2010;21(1):30\u20134.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"2518_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2174\/1574887114666181204105208","volume":"14","author":"F Meriggi","year":"2019","unstructured":"Meriggi F. Malignant pleural effusion: still a long way to go. Rev Recent Clin Trials. 2019;14(1):24\u201330.","journal-title":"Rev Recent Clin Trials"},{"issue":"4","key":"2518_CR18","first-page":"303","volume":"96","author":"A Rozman","year":"2018","unstructured":"Rozman A, Mok TSK. Is the LENT score already outdated? respiration. Int Rev Thorac Dis. 2018;96(4):303\u20134.","journal-title":"Int Rev Thorac Dis."},{"issue":"4","key":"2518_CR19","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1183\/09031936.00167407","volume":"32","author":"SG Wu","year":"2008","unstructured":"Wu SG, Gow CH, Yu CJ, et al. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J. 2008;32(4):924\u201330.","journal-title":"Eur Respir J"},{"key":"2518_CR20","unstructured":"Edelman MJ, Hodgson L Fau - Wang X, Wang X Fau - Christenson R, et al. Serum vascular endothelial growth factor and COX-2\/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. (1556\u20131380 (Electronic))."},{"issue":"2\u20133","key":"2518_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0169-5002(01)00200-8","volume":"33","author":"JH Choi","year":"2001","unstructured":"Choi JH, Kim HC, Lim HY, et al. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer 2001;33(2\u20133):171\u20139.","journal-title":"Lung Cancer"},{"issue":"4","key":"2518_CR22","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1183\/09031936.05.00037004","volume":"25","author":"U Sack","year":"2005","unstructured":"Sack U, Hoffman M, Zhao XJ, et al. Vascular enclothelial growth factor in pleural effusions of different origin. Eur Respir J. 2005;25(4):600\u20134.","journal-title":"Eur Respir J."},{"issue":"7","key":"2518_CR23","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s002620050592","volume":"48","author":"H Yanagawa","year":"1999","unstructured":"Yanagawa H, Takeuchi E, Suzuki Y, Ohmoto Y, Bando H, Sone S. Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother. 1999;48(7):396\u2013400.","journal-title":"Cancer Immunol Immunother."},{"issue":"5","key":"2518_CR24","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejim.2007.09.014","volume":"19","author":"S Bielsa","year":"2008","unstructured":"Bielsa S, Salud A, Mart\u00ednez M, et al. Prognostic significance of pleural fluid data in patients with malignant effusion. Eur J Intern Med. 2008;19(5):334\u20139.","journal-title":"Eur J Intern Med"},{"issue":"5\u20136","key":"2518_CR25","first-page":"278","volume":"70","author":"J Zych","year":"2002","unstructured":"Zych J, Szturmowicz M, Sakowicz A, et al. Neuron-specific enolase (NSE) serum level as a prognostic factor in non-small cell lung cancer. Pneumonol Alergol Pol. 2002;70(5\u20136):278\u201383.","journal-title":"Pneumonol Alergol Pol"},{"key":"2518_CR26","doi-asserted-by":"crossref","first-page":"107327482110531","DOI":"10.1177\/10732748211053150","volume":"29","author":"YY Ma","year":"2022","unstructured":"Ma YY, Wang H, Zhao WD, et al. Prognostic value of combined lactate dehydrogenase, C-reactive protein, cancer antigen 153 and cancer antigen 125 in metastatic breast cancer. Cancer Control. 2022;29:10732748211053150.","journal-title":"Cancer Control"},{"issue":"1","key":"2518_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00408-015-9831-6","volume":"194","author":"A Verma","year":"2016","unstructured":"Verma A, Abisheganaden J, Light RW. Identifying malignant pleural effusion by a cancer ratio (Serum LDH: Pleural Fluid ADA Ratio). Lung. 2016;194(1):147\u201353.","journal-title":"Lung"},{"key":"2518_CR28","doi-asserted-by":"publisher","first-page":"7348239","DOI":"10.1155\/2016\/7348239","volume":"2016","author":"A Verma","year":"2016","unstructured":"Verma A, Dagaonkar RS, Marshall D, Abisheganaden J, Light RW. Differentiating malignant from tubercular pleural effusion by cancer ratio plus (cancer ratio: pleural lymphocyte count). Can Respir J. 2016;2016:7348239.","journal-title":"Can Respir J"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-022-02518-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-022-02518-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-022-02518-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T08:05:28Z","timestamp":1645689928000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-022-02518-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2518"],"URL":"https:\/\/doi.org\/10.1186\/s12935-022-02518-w","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,24]]},"assertion":[{"value":"10 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}